PLX Protalix BioTherapeutics Inc. (DE)

0.3
-0.01  -2%
Previous Close 0.31
Open 0.32
Price To Book -0.63
Market Cap 45,078,542
Shares 148,382,299
Volume 453,900
Short Ratio 1.73
Av. Daily Volume 1,381,706
Stock charts supplied by TradingView

NewsSee all news

  1. Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease

    CARMIEL, Israel, Nov. 27, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  2. Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

    CARMIEL, Israel, Nov. 18, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  3. Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

    CARMIEL, Israel, Nov. 7, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  4. Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  5. Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 completion of enrolment announced September 24, 2019.
Pegunigalsidase alfa (PRX-102) - BALANCE
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
OPRX-106
Ulcerative Colitis
BLA filing due April 2019.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 3 completion of enrolment announced June 17, 2019.
Pegunigalsidase alfa (PRX-102) - BRIGHT
Fabry disease

Latest News

  1. Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease

    CARMIEL, Israel, Nov. 27, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  2. Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

    CARMIEL, Israel, Nov. 18, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  3. Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

    CARMIEL, Israel, Nov. 7, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  4. Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  5. Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  6. Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

    CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins

  7. Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

    CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins